March 8, 2025 - 23:35

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis (AD) are particularly affected by social determinants of health, further impacting their outcomes. Research indicates that various factors, including socioeconomic status, access to healthcare, and environmental conditions, play a crucial role in the management and treatment of AD in these communities.
Children of color often experience barriers such as inadequate healthcare access, lack of insurance, and transportation challenges, which can hinder timely and effective treatment. These obstacles not only exacerbate the severity of the condition but also lead to a cycle of poor health outcomes and increased healthcare costs.
Addressing these social determinants is essential for improving the quality of care for pediatric patients with AD. Initiatives aimed at increasing awareness, enhancing access to specialists, and providing community support can significantly impact the management of atopic dermatitis in these vulnerable populations. By prioritizing these factors, healthcare systems can work towards achieving equitable health outcomes for all children, regardless of their background.
July 21, 2026 - 17:42
Rare disease drugmakers try to avoid Trump price cutsPharmaceutical companies that specialize in treatments for rare diseases are scrambling to shield their products from possible price cuts under a potential second Trump administration. During his...
July 21, 2026 - 06:41
The rise of Zyn-like pouches for sleep, health, focus, teethThe success of Zyn nicotine pouches has sparked a wave of copycat products that promise to deliver everything from better sleep to sharper focus, all through a small pouch tucked inside the lip....
July 20, 2026 - 19:14
FDA says it’s still investigating Taylor Farms in cyclosporiasis outbreakThe U.S. Food and Drug Administration has clarified that a false-positive lab result does not alter the `overwhelming epidemiological data` pointing to Taylor Farms as the source of a...
July 20, 2026 - 11:31
Seven peptides are under review by an FDA panel this week. Here’s everything we knowA federal advisory committee is set to meet this week to evaluate seven peptide products, a move that could reshape how these compounds are made and prescribed in the United States. The panel,...